SG11201809838VA - Method of treating lower tract urothelial cancer - Google Patents

Method of treating lower tract urothelial cancer

Info

Publication number
SG11201809838VA
SG11201809838VA SG11201809838VA SG11201809838VA SG11201809838VA SG 11201809838V A SG11201809838V A SG 11201809838VA SG 11201809838V A SG11201809838V A SG 11201809838VA SG 11201809838V A SG11201809838V A SG 11201809838VA SG 11201809838V A SG11201809838V A SG 11201809838VA
Authority
SG
Singapore
Prior art keywords
international
lexington
lower tract
christo
pher
Prior art date
Application number
SG11201809838VA
Other languages
English (en)
Inventor
Dennis Giesing
Christopher Cutie
Purnanand Sarma
Cheryl Larrivee-Elkins
Christopher Searcy
Vikas Agarwal
Original Assignee
Taris Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical Llc filed Critical Taris Biomedical Llc
Publication of SG11201809838VA publication Critical patent/SG11201809838VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0216—Materials providing elastic properties, e.g. for facilitating deformation and avoid breaking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Materials For Medical Uses (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
SG11201809838VA 2016-05-06 2017-05-05 Method of treating lower tract urothelial cancer SG11201809838VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662333151P 2016-05-06 2016-05-06
US201762443614P 2017-01-06 2017-01-06
PCT/US2017/031445 WO2017193098A1 (en) 2016-05-06 2017-05-05 Method of treating lower tract urothelial cancer

Publications (1)

Publication Number Publication Date
SG11201809838VA true SG11201809838VA (en) 2018-12-28

Family

ID=60203435

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201809838VA SG11201809838VA (en) 2016-05-06 2017-05-05 Method of treating lower tract urothelial cancer
SG10201913416PA SG10201913416PA (en) 2016-05-06 2017-05-05 Method of treating lower tract urothelial cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201913416PA SG10201913416PA (en) 2016-05-06 2017-05-05 Method of treating lower tract urothelial cancer

Country Status (21)

Country Link
US (1) US20190388338A1 (ru)
EP (2) EP3452053B1 (ru)
JP (3) JP2019514970A (ru)
KR (2) KR20220123317A (ru)
CN (2) CN109475571A (ru)
AU (1) AU2017261371B2 (ru)
CA (1) CA3023274A1 (ru)
ES (1) ES2940227T3 (ru)
FI (1) FI3452053T3 (ru)
HR (1) HRP20221544T1 (ru)
HU (1) HUE060965T2 (ru)
IL (2) IL295592A (ru)
LT (1) LT3452053T (ru)
MX (2) MX2018013432A (ru)
PL (1) PL3452053T3 (ru)
PT (1) PT3452053T (ru)
RS (1) RS64032B1 (ru)
RU (2) RU2022100624A (ru)
SG (2) SG11201809838VA (ru)
SI (1) SI3452053T1 (ru)
WO (1) WO2017193098A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI843168B (zh) 2016-10-11 2024-05-21 美商艾吉納斯公司 抗ｌａｇ－３抗體及其使用方法
CA3071014A1 (en) * 2017-07-25 2019-01-31 Taris Biomedical Llc Methods of treating tumor metastasis
AU2018366106A1 (en) 2017-11-08 2020-05-14 Taris Biomedical Llc Methods of treatment and maintenance therapy for bladder cancer using gemcitabine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY30915A1 (es) * 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
US10543166B2 (en) 2009-06-26 2020-01-28 Taris Biomedical Llc Implantable drug delivery devices and methods of making the same
HUE053888T2 (hu) 2009-12-17 2021-07-28 Taris Biomedical Llc Intravezikálisan tolerálható beültethetõ eszköz
MX343671B (es) * 2010-06-02 2016-11-16 Abraxis Bioscience Llc * Metodos de tratamiento de cancer de vejiga.
DK2600800T3 (da) 2010-08-05 2020-11-16 Taris Biomedical Llc Indretning til lægemiddellevering i en ureterstent og kit dertil
JP6043730B2 (ja) 2011-02-04 2016-12-14 タリス バイオメディカル エルエルシー 低溶解性薬物の制御された放出のための植込み型装置
CA2868431A1 (en) * 2012-03-29 2013-10-03 Altor Bioscience Corporation Methods for treating neoplasia
SG11201501424SA (en) 2012-08-31 2015-03-30 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer comprising oxaliplatin
BR112015004110A2 (pt) 2012-08-31 2017-07-04 Taris Biomedical Llc sistemas e métodos de distribuição de drogas para tratamento de próstata
US10137287B2 (en) 2013-03-05 2018-11-27 Taris Biomedical Llc Drug delivery devices and methods for controlled drug release through device orifice
CA2903164C (en) 2013-03-15 2024-06-11 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
RU2669407C2 (ru) 2013-03-15 2018-10-11 ТАРИС Биомедикал ЛЛК Устройства для доставки лекарственных средств и способы доставки лекарственных средств
EP3035991B1 (en) 2013-08-19 2020-07-08 TARIS Biomedical LLC Multi-unit drug delivery devices
KR102338079B1 (ko) * 2014-03-06 2021-12-09 타리스 바이오메디컬 엘엘씨 젬시타빈으로 방광암을 치료하기 위한 약물 전달 시스템 및 방법
EP3517099B1 (en) 2014-06-26 2022-12-28 TARIS Biomedical LLC Intravesical drug delivery devices and methods including elastic polymer-drug matrix systems
JP7425534B2 (ja) 2015-04-23 2024-01-31 タリス バイオメディカル エルエルシー 薬物透過性構成要素を有する薬物送達デバイス及び方法

Also Published As

Publication number Publication date
SG10201913416PA (en) 2020-03-30
US20190388338A1 (en) 2019-12-26
EP3452053B1 (en) 2022-12-14
CN118453872A (zh) 2024-08-09
EP3452053A4 (en) 2019-12-25
LT3452053T (lt) 2023-02-10
AU2017261371A1 (en) 2018-12-13
JP2019514970A (ja) 2019-06-06
CA3023274A1 (en) 2017-11-09
WO2017193098A1 (en) 2017-11-09
KR20190005204A (ko) 2019-01-15
BR112018072551A2 (pt) 2019-02-19
FI3452053T3 (fi) 2023-04-12
JP2022009327A (ja) 2022-01-14
MX2018013432A (es) 2019-08-12
PT3452053T (pt) 2023-03-03
RU2018142908A3 (ru) 2020-08-31
EP4209221A1 (en) 2023-07-12
HRP20221544T1 (hr) 2023-02-17
RU2764747C2 (ru) 2022-01-20
IL262746A (en) 2018-12-31
PL3452053T3 (pl) 2023-05-08
IL295592A (en) 2022-10-01
EP3452053A1 (en) 2019-03-13
HUE060965T2 (hu) 2023-04-28
JP2024028881A (ja) 2024-03-05
ES2940227T3 (es) 2023-05-04
RS64032B1 (sr) 2023-04-28
RU2018142908A (ru) 2020-06-08
KR20220123317A (ko) 2022-09-06
KR102435709B1 (ko) 2022-08-25
IL262746B (en) 2022-09-01
RU2022100624A (ru) 2022-02-09
SI3452053T1 (sl) 2023-03-31
CN109475571A (zh) 2019-03-15
MX2021013461A (es) 2021-12-10
AU2017261371B2 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201808125RA (en) Methods for solid tumor treatment
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201909960UA (en) Methods for improving memory and cognition and for treating memory and cognitive disorders
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201903155XA (en) Pharmaceutical compounds
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201805281YA (en) Resource allocation for computer processing
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201903892UA (en) [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
SG11201909837YA (en) Methods for treating lung disorders
SG11201901228QA (en) Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide
SG11201408750VA (en) NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201900361RA (en) Methods of treating prostate cancer
SG11201810940XA (en) Methods of treating pancreatic cancer
SG11201803692PA (en) Anti-5t4 antibodies and antibody-drug conjugates
SG11201909840TA (en) Treatment of epithelial cysts by intracystic injection of antineoplastic particles
SG11201909107YA (en) Stenosis treatment
SG11201809838VA (en) Method of treating lower tract urothelial cancer